We are actively seeking collaboration opportunities that will help to accelerate the development and commercialization of our novel innate immune checkpoint inhibitor (ICI), ASD141.

ICIs have shown great promise in a wide spectrum of cancers, however there is limited clinical success in a large proportion of patients.

We are assessing opportunities to partner with companies which have the strongest science and capabilities in immuno-oncology. We will work together to realize innovation, achieve objective tumor responses, and prolong the survival of people living with the most devastating types of cancer.

Proposed Business Opportunities

  • Out-licensing of lead asset ASD141 for immuno-oncology (solid tumors) indication globally or regionally.
  • Co-development of ASD141 through Phase Ia and Phase Ib trials with negotiation on later stage clinical development and commercialization.
  • Out-licensing of ASD253 therapeutic vaccine for HBV globally or regionally.

Why partner with Ascendo?

  1. Ascendo’s novel approach enables a powerful anti-tumor response

ASD141 targets TLT-1, a key regulatory protein that induces the immune suppressive environment in the tumor. There is a direct correlation between high concentrations of TLT-1 in the tumor microenvironment (TME) and poor prognosis, but until now TLT-1 has not been utilized for treating solid tumors. ASD141 works by blocking TLT-1 and reinvigorating the cells that coordinate an immune response in the tumor microenvironment.

  1. Ascendo harnesses the potential of the innate and adaptive immune systems

Overcoming bottlenecks in cancer immunotherapy requires effective cross-talk between the innate and adaptive immune pathways. Our approach targets the innate pathway which holds the potential to deliver better regulation of cancer by activating natural control pathways.

  1. Ascendo is leading scientific advances in immune-oncology

We have extensive knowledge of the key binding domains that trigger immune activation and conclusive knowledge on the role of TLT-1 in immune suppression. Our specifically designed antibody, ASD141, binds to the CD11b subunit on the Mac-1 receptor and prevents TLT-1 from binding to this portion of the receptor.

  1. ASD141 has potential for use in monotherapy and in combination with targeted agents

ASD141 monotherapy achieves tumor suppression comparable with Keytruda® in a humanized animal model and increases tumor suppression when used in combination with current therapies, anti-PD1/ anti-PDL1 and CTLA4. Read more.

Interested in partnering with us?

Ascendo Biotechnology is a strategic partner of choice for novel immunotherapies which exploit the interplay between the innate and adaptive immune response. We are currently seeking partners to accelerate the development and commercialization of our lead oncology drug, ASD141.

If you’re interested in discussing a potential partnership, please get in touch:

Contact Us